The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | NEOD001 in amyloidosis
Morie Hertz, MD, MACO from the Mayo Clinic College of Medicine, Rochester, MN discusses the use of the novel monoclonal antibody, NEOD-001, in the treatment of amyloidosis. Several studies have been conducted to explore the effect of NEOD-001 on amyloidosis and some success has been observed. Therefore, there is a potential of the investigation to extend into the use of NEOD in the treatment of kidney amyloidosis and other forms of amyloidosis. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
